DV Trading Expands Holdings
DV Trading Significantly Boosts Stakes in Valaris, Morgan Stanley, and Biotech Stocks
Anonymous
Key Points
1
Valaris opened at $79.25 on Friday, and DV Trading LLC increased its stake to 16,900 shares, worth about $1.66 million at the end of the latest quarter.
2
DV Trading added 714,000 shares of CytomX Therapeutics (CTMX), valued at approximately $3.356 million, making it the 19th largest holding and accounting for about 0.1% of its portfolio.
3
Morgan Stanley (MS) position rose to 4,276 shares (up 3,776) for about $704,000, reflecting DV Trading’s broader activity in financial services; the stock remains part of a heavily institutional-held universe, including Norges Bank initiating a new MS position in Q4 worth about $2.74 billion and Vanguard owning roughly 119.7 million MS shares.
4
Compass Therapeutics (CMPX) position reached 423,566 shares, valued around $2.241 million, making CMPX the 19th largest holding for DV; hedge funds own about 68.43% of CMPX, and the stock opened at $1.91 in intraweek trading.
DV Trading LLC made sweeping moves in the first quarter, dramatically expanding positions across energy, biotech, and financial services. The firm's stake in offshore driller Valaris jumped 5,533.3% to 16,900 shares, worth about $1.66 million, according to Watchlist News.
The Chicago-based trading firm also opened a new position in CytomX Therapeutics, buying 714,000 shares valued at roughly $3.36 million. That single move made CTMX one of DV Trading's most notable new bets of the quarter.
Valaris Stake Surges Over 5,500% in One Quarter
DV Trading's Valaris position went from nearly nothing to 16,900 shares in just three months. Valaris, an offshore oil drilling company, opened at $79.25 on Friday. At that price, DV Trading's stake is worth about $1.66 million. The 5,533.3% increase is one of the sharpest moves the firm made in the quarter, according to Watchlist News.
Institutional investors have long held large chunks of offshore drillers. DV Trading's rapid build-up in Valaris suggests growing confidence in the energy sector's near-term outlook. The firm appears to be making targeted, high-conviction bets rather than spreading money thinly across many names.
CytomX and Compass Therapeutics Lead Biotech Push
DV Trading opened a brand-new position in CytomX Therapeutics, snapping up 714,000 shares worth about $3.36 million. That makes CTMX roughly 0.1% of DV Trading's total portfolio. It also ranks as one of the firm's 19th largest holdings, according to Ticker Report.
Compass Therapeutics was another biotech target. DV Trading boosted its CMPX position to 423,566 shares, valued at around $2.24 million. The stock opened at $1.91 in recent intraweek trading. Hedge funds already own about 68.43% of Compass Therapeutics, showing the stock is a popular pick among institutional investors, per Ticker Report.
Morgan Stanley Position Jumps 755% as Big Funds Circle
DV Trading added 3,776 shares of Morgan Stanley in the quarter, lifting its total to 4,276 shares worth roughly $704,000. That is a 755.2% jump in a single quarter. Morgan Stanley is heavily owned by large institutions, according to Ticker Report.
Norges Bank started a brand-new Morgan Stanley position in Q4 worth about $2.74 billion. Vanguard owns roughly 119.7 million MS shares. DV Trading's move is small next to those giants, but it fits a pattern of the firm quietly building exposure to big financial names alongside the world's largest funds.
DV Trading's Broad Strategy: Energy, Biotech, and Finance
DV Trading also put $1.16 million into Vaxcyte, buying 20,000 shares of the vaccine company, according to Watchlist News. Separately, the firm picked up 360,064 shares of Avalo Therapeutics worth $5.376 million, per Ticker Report. That makes Avalo 0.1% of DV Trading's portfolio.
Taken together, DV Trading's Q1 activity shows a firm hunting across very different industries. It is not chasing one theme. Instead, it is building positions in offshore drilling, biotech drugs, and Wall Street banks all at once. The sizes are modest, but the breadth signals an opportunistic, diversified approach to the market.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
11
Reach
24
A
AnonymousAuthor